Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood

Volumn 129, Issue 19, 2017, Pages 2680-2692

  Schroeder, Mark A ^a   Rettig, Michael P ^a   Lopez, Sandra ^a   Christ, Stephanie ^a   Fiala, Mark ^a   Eades, William ^a   Mir, Fazia A ^b   Shao, Jin ^a   McFarland, Kyle ^a   Trinkaus, Kathryn ^a   Shannon, William ^a   Deych, Elena ^a   Yu, Jinsheng ^a   Vij, Ravi ^a   Stockerl Goldstein, Keith ^a   Cashen, Amanda F ^a   Uy, Geoffrey L ^a   Abboud, Camille N ^a   Westervelt, Peter ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PLERIXAFOR; TACROLIMUS; CD34 ANTIGEN; HETEROCYCLIC COMPOUND; TRANSCRIPTOME;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APHERESIS; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BLOATING; BLOOD DONOR; BRADYCARDIA; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG EFFICACY; ELECTROCARDIOGRAPH; ENGRAFTMENT; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENOTYPE; GRAFT RECIPIENT; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MORNING DOSAGE; MORTALITY; NEUTROPHIL COUNT; OPEN STUDY; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; SEPSIS; SIBLING; STEM CELL MOBILIZATION; T LYMPHOCYTE; VIREMIA; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; DONOR; DRUG EFFECTS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL; PROCEDURES;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELLS; TISSUE DONORS; TRANSCRIPTOME; TRANSPLANTATION, HOMOLOGOUS;

EID: 85019680459     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-739722     Document Type: Article

References (35)

1. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22): 5074-5087.
2. Chang YJ, Weng CL, Sun LX, Zhao YT. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-toevent data from randomized controlled trials. Ann Hematol. 2012;91(3):427-437.
3. Nagler A, Labopin M, Shimoni A, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reducedintensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(9):1422-1429.
4. Varmavuo V, Mantymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89(2):128-135.
5. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012; 26(1):34-53.
6. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990-998.
7. Holig K. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother. 2013;40(4): 225-235.
8. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17): 3917-3924.
9. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37(2):1253-1262.
10. Genzyme. Investigator's Brochure for Plerixafor Injection (AMD3100, Mozobil). http://www. mozobil.com/healthcare. Accessed 26 March 2017.
11. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44(6):1667-1673.
12. Cohen KS, Cheng S, Larson MG, et al. Circulating CD34(1) progenitor cell frequency is associated with clinical and genetic factors. Blood. 2013; 121(8):e50-e56.
13. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA. 2002;99(18):11872-11877.
14. Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood. 2008;112(9):3543-3553.
15. Blom B, Ho S, Antonenko S, Liu YJ. Generation of interferon alpha-producing predendritic cell (Pre- DC)2 from human CD34(1) hematopoietic stem cells. J Exp Med. 2000;192(12):1785-1796.
16. Dlubek D, Drabczak-Skrzypek D, Lange A. Low CXCR4 membrane expression on CD34(1) cells characterizes cells mobilized to blood. Bone Marrow Transplant. 2006;37(1):19-23.
17. Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol. 2006;34(8):1052-1059.
18. Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009;11(8):992-1001.
19. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 2006;107(9):3772-3778.
20. Levesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol. 2003;31(2):109-117.
21. Oelschlaegel U, Bornhauser M, Boxberger S, et al. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol. 2007;86(8):569-573.
22. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial preemptive therapy delayed until threshold CMV load . or 510000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 2006;37(1): 51-56.
23. Bertani G, Santoleri L, Martino M, et al. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. Transfusion. 2014;54(8):2028-2033.
24. Billen A, Madrigal JA, Szydlo RM, Shaw BE. Female donors and donors who are lighter than their recipient are less likely to meet the CD341 cell dose requested for peripheral blood stem cell transplantation. Transfusion. 2014;54(11): 2953-2960.
25. DiPersio JF. Diabetic stem-cell "mobilopathy." N Engl J Med. 2011;365(26):2536-2538.
26. Ferraro F, Lymperi S, Mendez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med. 2011;3(104):104ra101.
27. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-1056.
28. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colonystimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89(4): 229-235.
29. Benboubker L, Watier H, Carion A, et al. Association between the SDF1-39A allele and high levels of CD34(1) progenitor cells mobilized into peripheral blood in humans. Br J Haematol. 2001;113(1):247-250.
30. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527(1-3):255-262.
31. Kawaguchi A, Orba Y, Kimura T, et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood. 2009;114(14):2961-2968.
32. Kean LS, Sen S, Onabajo O, et al. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood. 2011;118(25): 6580-6590.
33. Lundqvist A, Smith AL, Takahashi Y, et al. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol. 2013;191(12):6241-6249.
34. Lonial S, Akhtari M, Kaufman J, et al. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocytemacrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biol Blood Marrow Transplant. 2013;19(3): 460-467.
35. Waller EK, Logan BR, Harris WA, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol. 2014;32(22): 2365-2372.